Andrographolide Sulfonate Injection for Adjunctive Treatment of Non-severe Community-Acquired Pneumonia in Adults: A Multicenter, Double-Blind, Randomized Controlled Trial.

In 30 seconds

This multicenter, double-blind, placebo-controlled randomized trial evaluated adjunctive andrographolide sulfonate (AS) injection in adults hospitalized with non-severe community-acquired pneumonia receiving standard therapy. Among 482 participants, median time to clinical stability was 1 h shorter with AS than placebo (HR 1.440; 95% CI 1.194, 1.736; log rank P<0.01), and initial treatment failure was less frequent (6.3% vs. 16.0%, P<0.01). Fever recovery was also faster, while hospital stay, intravenous antibiotic duration, and hospitalization cost did not differ significantly. The authors characterized the absolute clinical benefits as marginal.

Key findings

• Median time to clinical stability was 1 h shorter with AS than control (HR 1.440; 95% CI 1.194, 1.736; log rank P<0.01).
• Initial treatment failure occurred in 6.3% vs. 16.0% of patients (P<0.01), favoring adjunctive AS.
• Median time to fever recovery was 5 h shorter with AS (HR 1.461; 95% CI 1.150, 1.857; log rank P<0.01).
• At least 1 adverse event occurred in 41.5% with AS and 40.6% with control; hospital stay, intravenous antibiotic duration, and hospitalization cost did not differ significantly.

Why it matters

The trial suggests that adjunctive AS may modestly accelerate clinical stability and reduce initial treatment failure in hospitalized adults with non-severe CAP. However, the reported gains were small in absolute terms, and no significant differences were found in hospital stay, antibiotic duration, or cost. These results help frame the potential benefit alongside safety and resource-use outcomes.

What to keep in mind

The study enrolled hospitalized adults with non-severe CAP, so its findings may not apply to other populations or care settings. The authors describe the absolute clinical benefits as marginal.